Year-end review for colon cancer device?:
This article was originally published in Clinica
Executive Summary
SpectraScience has said it is confident that the US FDA will review its premarket approval (PMA) application for the Optical Biopsy system for colorectal cancer later this year. The Minneapolis, Minnesota-based company met with the FDA in mid-July to discuss the PMA, which proposes the device's use as an adjunct to colonoscopy to avoid biopsy tissue removal. The next scheduled meeting of the FDA's gastroenterology and urology panel is November 18-19, the company pointed out.
You may also be interested in...
Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time
Small sterilizers told Medtech Insight that they were ready for the EPA’s controversial EtO emissions rule, while community advocates expressed concerns.
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.